Equities research analysts predict that Blueprint Medicines Corporation (NASDAQ:BPMC) will post $5.16 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Blueprint Medicines Corporation’s earnings, with estimates ranging from $3.63 million to $5.94 million. Blueprint Medicines Corporation reported sales of $6.16 million during the same quarter last year, which indicates a negative year over year growth rate of 16.2%. The company is expected to announce its next earnings report on Thursday, November 9th.
According to Zacks, analysts expect that Blueprint Medicines Corporation will report full year sales of $5.16 million for the current year, with estimates ranging from $16.48 million to $23.61 million. For the next fiscal year, analysts forecast that the firm will report sales of $14.37 million per share, with estimates ranging from $4.50 million to $24.24 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Blueprint Medicines Corporation.
Blueprint Medicines Corporation (NASDAQ:BPMC) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.86) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.11). Blueprint Medicines Corporation had a negative net margin of 388.91% and a negative return on equity of 45.58%. The business had revenue of $5.89 million for the quarter, compared to analysts’ expectations of $5.96 million. During the same quarter last year, the business posted ($0.70) earnings per share. The business’s revenue was down 16.7% compared to the same quarter last year.
A number of equities research analysts have weighed in on BPMC shares. DA Davidson started coverage on shares of Blueprint Medicines Corporation in a report on Friday, September 29th. They issued a “buy” rating and a $90.00 price target for the company. Zacks Investment Research downgraded shares of Blueprint Medicines Corporation from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Canaccord Genuity upped their price target on shares of Blueprint Medicines Corporation from $56.00 to $66.00 and gave the company a “buy” rating in a report on Wednesday, September 20th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $79.00 price target (up from $64.00) on shares of Blueprint Medicines Corporation in a report on Wednesday, September 20th. Finally, BTIG Research started coverage on shares of Blueprint Medicines Corporation in a report on Friday, September 29th. They issued a “buy” rating and a $90.00 price target for the company. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $63.47.
In other Blueprint Medicines Corporation news, CEO Jeffrey W. Albers sold 30,000 shares of the company’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $49.62, for a total transaction of $1,488,600.00. Following the completion of the sale, the chief executive officer now directly owns 18,272 shares of the company’s stock, valued at $906,656.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kate Haviland sold 5,449 shares of the company’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $66.44, for a total transaction of $362,031.56. The disclosure for this sale can be found here. Insiders have sold 69,305 shares of company stock valued at $3,606,782 over the last ninety days. Insiders own 3.40% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. TimesSquare Capital Management LLC purchased a new stake in Blueprint Medicines Corporation during the second quarter valued at about $28,375,000. Bank of America Corp DE lifted its stake in Blueprint Medicines Corporation by 105.0% during the first quarter. Bank of America Corp DE now owns 8,090 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 4,144 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in Blueprint Medicines Corporation during the second quarter valued at about $1,368,000. Rhumbline Advisers lifted its stake in Blueprint Medicines Corporation by 62.6% during the second quarter. Rhumbline Advisers now owns 43,704 shares of the biotechnology company’s stock valued at $2,214,000 after buying an additional 16,825 shares in the last quarter. Finally, Swiss National Bank lifted its stake in Blueprint Medicines Corporation by 12.1% during the first quarter. Swiss National Bank now owns 46,300 shares of the biotechnology company’s stock valued at $1,852,000 after buying an additional 5,000 shares in the last quarter. 90.71% of the stock is owned by institutional investors.
Blueprint Medicines Corporation (NASDAQ BPMC) opened at 64.93 on Wednesday. Blueprint Medicines Corporation has a 12-month low of $25.08 and a 12-month high of $71.67. The firm’s 50-day moving average is $60.49 and its 200 day moving average is $49.20. The stock’s market capitalization is $2.54 billion.
TRADEMARK VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/27/analysts-anticipate-blueprint-medicines-corporation-bpmc-will-announce-quarterly-sales-of-5-16-million.html.
Blueprint Medicines Corporation Company Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Get a free copy of the Zacks research report on Blueprint Medicines Corporation (BPMC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.